Mayne Pharma GroupASX:MYX +7.53%51 PB Ratio is 0.59 as of Jun. 26, 2026, which is 24% below its 10-year median of 0.78. GuruFocus rates ASX:MYX with a GF Score™ of 51/100 and a GF Value™ of A$5.31 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 112 Medical Distribution companies, Mayne Pharma Group ranks better than 85.71% on this metric.
The historical rank and industry rank for Mayne Pharma Group's PB Ratio or its related term are showing as below:
ASX:MYX'
s PB Ratio Range Over the Past 10 Years
Min: 0.38 Med: 0.78 Max: 4.68
Current: 0.58
During the past 13 years, Mayne Pharma Group's highest PB Ratio was 4.68. The lowest was 0.38. And the median was 0.78.
ASX:MYX's PB Ratio is ranked better than 85.71% of 112
companies
in the Medical Distribution industry
Industry Median: 1.03
vs ASX:MYX: 0.58
During the past 12 months, Mayne Pharma Group's average Book Value Per Share Growth Rate was -21.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -10.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -16.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -7.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Mayne Pharma Group was 51.10% per year. The lowest was -24.20% per year. And the median was 7.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Mayne Pharma Group PB Ratio Related Terms
Mayne Pharma Group PB Ratio Historical Data
* Premium members only.
The historical data trend for Mayne Pharma Group's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Mayne Pharma Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mayne Pharma Group PB Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Mayne Pharma Group's PB Ratio distribution charts can be found below:
* The bar in red indicates where Mayne Pharma Group's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Mayne Pharma Group (ASX:MYX) has a PB Ratio of 0.59 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Mayne Pharma Group and its competitors. This is 24% below median its historical median of 0.78. Over the past decade, Mayne Pharma Group's PB Ratio has ranged from 0.38 to 4.68. According to the industry distribution chart, Mayne Pharma Group ranks #16 out of 112 companies in the Medical Distribution industry, placing it in the top 14.3%.
Is Mayne Pharma Group's PB Ratio too high?
Mayne Pharma Group's current PB Ratio of 0.59 is 24% below median its 10-year median of 0.78. Over the past 10 years, this metric has ranged from a low of 0.38 to a high of 4.68. The Medical Distribution industry median PB Ratio is 1.03. Mayne Pharma Group's value of 0.59 is 42.7% below this industry median. Based on the distribution chart, Mayne Pharma Group ranks #16 out of 112 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Mayne Pharma Group has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's PB Ratio compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Mayne Pharma Group ranks #16 out of 112 companies for PB Ratio. This places Mayne Pharma Group in the top 14% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.03. Mayne Pharma Group's value of 0.59 is 42.7% below this benchmark. Historically, Mayne Pharma Group's own PB Ratio has ranged from 0.38 to 4.68 over the past decade. While the company's 10-year median is 0.78 vs. the industry median of 1.03, Mayne Pharma Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Distribution company?
The median PB Ratio among Medical Distribution companies is 1.03, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mayne Pharma Group's current PB Ratio of 0.59 is 42.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Mayne Pharma Group and its competitors. For the Medical Distribution industry, the median PB Ratio is 1.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mayne Pharma Group's current PB Ratio is 0.59, which is 24% below median its own 10-year median of 0.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (ASX:MYX) is currently considered Possible Value Trap. The stock's GF Value™ is A$5.31, compared to a current price of A$2.57 — trading 51.6% below its estimated fair value. The current PB Ratio is 0.59, which is 24% below median its 10-year median of 0.78 and 42.7% below the Medical Distribution industry median of 1.03. Mayne Pharma Group's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Mayne Pharma Group (ASX:MYX), the current PB Ratio is 0.59 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mayne Pharma Group (ASX:MYX) Overvalued in 2026?
Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued.
The current stock price of A$2.57 is trading 51.6% below its estimated GF Value™ of A$5.31.
GuruFocus considers Mayne Pharma Group to be Possible Value Trap.
Key valuation signals for ASX:MYX:
PB Ratio: 0.59 (24% below median its 10-year median of 0.78)
GF Value™: A$5.31 vs. price of A$2.57 (51.6% below fair value)
Industry Position: 42.7% below the Medical Distribution median (#16 of 112)
No single metric tells the full story. See the ASX:MYX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
51GF Score
Get the complete analysis for ASX:MYX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MYX has been successfully added to your 
